Offstream
news

---

Changes

1. AstraZeneca’s vaccine candidate shows promise in older adults. Late-stage trails are expected to be released by Christmas.
   2020-11-20 07:04:10 (First version)
2. AstraZeneca’s vaccine candidate shows promise in older adults. Late-stage trials are expected to be released by Christmas.
   (Current version)

---

Related

Health Canada authorizes the use of the AstraZeneca's antibody-based therapy Evushield for immunocompromised patients aged above 12 years.
2022-04-14

AstraZeneca-Oxford developers say that their vaccine candidate is effective against the UK variant of SARS-CoV-2.
2021-02-5

Kyrgyzstan is expected to receive 504,000 doses of the Oxford-AstraZeneca vaccine in March.
2021-02-2

Brazil begins distribution of the AstraZeneca-Oxford University vaccine.
2021-01-23

India approves the emergency use of the vaccine developed by the University of Oxford and AstraZeneca, becoming the third country in the world to do so after the United Kingdom and Argentina.
2021-01-1

El Salvador approves a vaccine made by the University of Oxford and AstraZeneca for use in the country.
2020-12-30

Malaysia signs a deal to receive 6.4 million doses of the AstraZeneca vaccine.
2020-12-22

AstraZeneca announces that they would resume vaccine trials in Japan.
2020-10-2

Prime Minister Justin Trudeau announces that the country has signed a deal with AstraZeneca to buy up to 20 million doses of its COVID-19 vaccine.
2020-09-25

The United States Department of Defense says that the United States military will choose five treatment facilities to carry advanced testing phases for AstraZeneca and other vaccine trials.
2020-09-3